Adalimumab Biosimilar Report covers the updated marketed and pipeline drug profiles, including clinical and non-clinical stage products, and highlights the inactive pipeline products. It also includes the therapeutics assessment by product type, stage, route of administration, and molecule type.
Adalimumab Biosimilar Report Highlights
Humira (adalimumab) is a recombinant human IgG1 monoclonal antibody indicated for alleviating signs and symptoms and prohibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
DelveInsight’s Adalimumab Biosimilar Insight report provides an analysis of several drugs in different clinical development stages, covering marketed, phase III, II, I, and preclinical. It also helps to comprehend clinical trial details, expressive pharmacological action, agreements, and collaborations.
Download Free Sample Report, Request @ Adalimumab Biosimilar Pipeline Analysis
Adalimumab Biosimilars Marketed Drugs
Abrilada is an FDA-approved biosimilar version of adalimumab. Abrilada (adalimumab-afzb) injection is administered as a sterile, preservative-free solution for subcutaneous administration. Though sanctioned, it is not yet marketed in the US like various other manufacturers of authorized biosimilar versions of adalimumab, Pfizer has signed a licensing contract with AbbVie; under the deal, Samsung might launch the drug in November 2023.
Halimatoz is mostly used in adults when their conditions are severe, moderately severe or exacerbated, or when patients cannot use other treatments. Halimatoz comprises the active substance adalimumab and is a biosimilar medicine. The active substance in Halimatoz, adalimumab, is a monoclonal antibody that has been designed to identify and attach to a substance in the body called tumour necrosis factor (TNF). TNF is involved in causing inflammation and is presented at high levels in patients with the diseases that Halimatoz is used for treatment. By attaching to TNF, adalimumab inhibits its activity, thereby lessening inflammation and other symptoms of the diseases.
For further product profiles, access @ Adalimumab Biosimilars Marketed Drugs
Scope of Adalimumab Biosimilars Report:
Table of Contents
1
Key Insights
2
Adalimumab Biosimilars: Snapshot
3
Adalimumab Biosimilars Executive Summary
4
Regulatory Outlook For Biosimilars
4.1.
North America
4.2.
Europe
4.3.
Asia Pacific
4.4.
Rest Of The World
5
Adalimumab (Humira)
6
Research and Development
7
Remicade Biosimilar Emerging Opportunities
8
Adalimumab Biosimilars Assessment
9
Adalimumab Biosimilars Profiles: By Company
9.1.
Abrilada: Pfizer
9.2.
Hulio: Fujifilm Kyowa Kirin Biologics
9.3.
HLX 03: Shanghai Henlius Biotech
9.4.
Pamera: Hetero Biopharma
9.5.
Qletli: Bio-Thera Solutions
10
Adalimumab Biosimilars Comparative Landscape: By Company
11
Adalimumab Biosimilars Competitive Landscape
12
Adalimumab Biosimilars Market Drivers
13
14
Adalimumab Biosimilars SWOT Analysis
15
Appendix
16
Bibliography
17
DelveInsight Capabilities
18
Disclaimer
19
About DelveInsight
Browse Detailed TOC, Emerging Drugs and Key Companies @ https://www.delveinsight.com/report-store/adalimumab-biosimilars-insight
About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/adalimumab-biosimilars-insight